The inflammation industry primarily comprises biotech and pharmaceutical companies that focus on the treatment of cancer, inflammation, and other diseases related to cell proliferation. Noteworthy players in this domain include Karyopharm Therapeutics Inc., Allakos Inc., and Zymeworks.
Swing Trader: Medium Volatility Stocks for Active Trading (TA&FA) - Annualized Return + 60%
The most prominent companies in this sector are Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE), and Amgen (NASDAQ:AMGN).
Market Capitalization Insights
The average market capitalization across the inflammation theme stands at $67.2B. The range for individual tickers spans from a modest $13.8M to a staggering $448.3B. Johnson & Johnson (JNJ) holds the crown for the highest valuation at $448.3B, while FWP is on the other end of the spectrum, valued at $13.8M.
Recent Market Cap Movements:
Price Fluctuations and Noteworthy News
The average weekly price growth for stocks in the inflammation theme was -1.83%. On a monthly scale, the growth was 0.67%, and quarterly, it was 4.06%. ANAB led the pack with a price growth of 4.1%, while ALLK faced the steepest decline at -24.26%.
Significant Price Movements:
Volume Dynamics The inflammation theme experienced an average weekly volume growth of 90.97%. Monthly volume growth averaged at 251.01%, and quarterly growth was an impressive 398.6%.
Fundamental Analysis Ratings
The industry's average fundamental analysis ratings, where 1 represents the best and 100 the worst, are as follows: [Data not provided]
In conclusion, the inflammation industry stocks have showcased significant growth and activity over the past month. With an average gain of 8.36%, it's evident that this sector is one to watch closely in the financial landscape.
CHRS - On August 15, 2023, CHRS marked its third consecutive day of decline, registering a -4.49% downward trend. Historically, such a three-day fall is perceived negatively in the market. Analyzing past patterns, out of 332 instances where CHRS faced a three-day drop, it continued to decline in 277 cases in the subsequent month. This suggests an 83% likelihood of the stock's continued descent. Investors are advised to monitor CHRS closely.
PFE - On August 09, 2023, PFE witnessed a positive shift in its Moving Average Convergence Divergence (MACD) Histogram. Historical data reveals that when PFE's MACD has turned positive in the past, the stock experienced an upward trajectory in 24 out of 41 instances in the succeeding month. This indicates a 59% probability of the stock maintaining its upward momentum. Investors should keep a close watch on PFE's performance.
JNJ - On July 31, 2023, JNJ's 10-day RSI Oscillator transitioned from the overbought zone, hinting at a possible shift from an ascending to a descending trend. Investors might contemplate selling the stock or considering put options. An analysis by Tickeron's A.I.dvisor, based on 37 similar past events, revealed that in 22 instances, the stock's value decreased in the subsequent days. This suggests a 59% likelihood of a downward movement for JNJ in the near future. Investors are advised to proceed with caution.
CHRS broke above its upper Bollinger Band on August 28, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 34 similar instances where the stock broke above the upper band. In of the 34 cases the stock fell afterwards. This puts the odds of success at .
The 10-day RSI Indicator for CHRS moved out of overbought territory on September 05, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on September 12, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on September 08, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
CHRS moved below its 50-day moving average on September 18, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (72.993) is normal, around the industry mean (22.685). P/E Ratio (0.000) is within average values for comparable stocks, (131.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.923). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (2.000) is also within normal values, averaging (316.663).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of biologic therapeutics for oncology and inflammatory diseases
A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ATRA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ATRA could also see price increases.